Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Early-Stage HCC: Role of Adjuvant Therapy

June 29th 2022

A brief discussion on the risks of neoadjuvant immunotherapy in early-/intermediate-stage HCC with regard for liver transplantation candidacy.

Patient Profile 1: Resection for Early/Intermediate Stage HCC

June 29th 2022

Centering discussion on a patient with early/intermediate-stage HCC, expert panelists consider the roles of transplant, resection, and adjuvant therapy, respectively.

HER-Vaxx Plus Chemotherapy Improves OS in HER2+ Advanced Gastric/GEJ Cancer

June 28th 2022

The addition of the HER2-Vaxx vaccine to standard-of-care chemotherapy led to a significant improvement in overall survival vs SOC chemotherapy alone in patients with HER2-neu overexpressing advanced and metastatic gastric and gastroesophageal junction cancer.

Dr. Botta on Unmet Needs in the Salvage Setting of GI Cancers

June 28th 2022

Gregory Botta, MD, PhD, discusses unmet needs in the salvage setting of gastrointestinal cancers.

Dr. Khorana on Rates of Young-Onset Pancreatobiliary Adenocarcinoma

June 24th 2022

Alok Khorana, MD, discusses increasing rates of young-onset pancreatobiliary adenocarcinoma.

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

June 24th 2022

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Khan Casts Light on Disparities in Surgical Care of GI Tract Cancer

June 23rd 2022

Dr Khan expands on key data found on racial disparities in surgical outcomes for gastrointestinal tract cancer and addresses the need to reduce the gap in these outcomes.

HPN328 Elicits Antitumor Activity in Small Cell Lung Cancer and Other NETs

June 23rd 2022

HPN328, a novel half-life extended DLL3-targeting T-cell engager, demonstrated clinical activity and tolerability in patients with pretreated small cell lung cancer and other neuroendocrine tumors, according to findings from a phase 1/2 study (NCT04471727).

Dr. Botta on the Rationale of Investigating CT041 in Gastric and Pancreatic Cancers

June 19th 2022

Gregory Botta, MD, PhD, discusses the rationale for investigating CT041 in patients with advanced gastric and pancreatic cancers in a phase 1b trial.

Dr. Khan on the Rationale of Examining Disparate Outcomes in GI Tract Cancer Surgery

June 19th 2022

Sajid A. Khan MD, FACS, FSSO, discusses the rationale of examining disparate outcomes in gastrointestinal tract cancer surgery.

Efforts Are Needed to Address the Enigmatic Rise of Young-Onset Gastrointestinal Cancers

June 16th 2022

Despite a steady decline in incidence and mortality rates of many cancers among older individuals in the United States and other high-income countries, an alarming rise in young-onset gastrointestinal cancers has simultaneously occurred.

Overview of Molecular Testing in Colorectal Cancer

June 15th 2022

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

Dr. Kahn on Next Steps on Examining Racial Disparities in GI Cancer

June 15th 2022

Sajid A Khan MD, FACS, FSSO, discusses next steps in examining racial disparities in gastrointestinal tract cancer.

Nivolumab/Ipilimumab and Nivolumab/Chemo Indications Enhance ESCC Treatment Landscape

June 15th 2022

The approval of 2 nivolumab-containing combinations for patients with advanced or metastatic esophageal squamous cell carcinoma have opened the doors for immunotherapy to enter the landscape for this population allowing clinicians options to help patients to meet their individual treatment goals.

Sotorasib Produces Encouraging Antitumor Activity in Heavily Pretreated KRAS G12C–Mutated Pancreatic Cancer

June 14th 2022

Sotorasib demonstrated clinically meaningful activity and acceptable tolerability in heavily pretreated patients with KRAS G12C–mutated advanced pancreatic cancer, according to date from the single-arm, phase 1/2 CodeBreak 100 trial.

Insights on Existing and Prospective Second-line Treatment Strategies for Patients With ESCC

June 14th 2022

Thoughtful discussion of existing and emerging second-line treatment options for patients with metastatic ESCC

First-line Treatment Approaches and Considerations for Patients With Metastatic ESCC

June 14th 2022

Focusing on metastatic ESCC, John Marshall, MD, discusses selecting appropriate first-line treatment strategies for patients.

Hua Highlights Innovative Research With Immunotherapy in NETs

June 9th 2022

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.

Trends and Disparities in Treatment Approaches for Patients With Locoregional ESCC

June 8th 2022

Shared insights on contemporary approaches to treating localized ESCC and existing racial disparities in treatment.